Related Articles
Dual specific CD19/CD22‑targeted chimeric antigen receptor T‑cell therapy for refractory diffuse large B‑cell lymphoma: A case report
Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
CAR‑T 19 combined with reduced‑dose PD‑1 blockade therapy for treatment of refractory follicular lymphoma: A case report
A phase I study of CAR‑T bridging HSCT in patients with acute CD19<sup>+</sup> relapse/refractory B‑cell leukemia
Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor